Evidence map›Paper›PMID 40921307›Full record

ArticleAmerican journal of preventive medicine2025

Trends in Prenatal Opioid Use Disorder in California, 2010-2022.

Sidra Goldman-Mellor, Jyotishman Pathak, Claire E Margerison

Abstract read
In one paragraph

Article in American journal of preventive medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sidra Goldman-MellorDepartment of Public Health, School of Social Sciences, Humanities and Arts, University of California, Merced, Merced, California; Health Sciences Research Institute, University of California, Merced, Merced, California. Electronic address: sgoldman-mellor@ucmerced.edu.
Jyotishman PathakDepartments of Population Health Sciences, Weill Cornell Medicine and Cornell University, New York, New York.
Claire E MargerisonDepartment of Epidemiology and Biostatistics, Michigan State University, East Lansing, Michigan.

Funding

Pregnancy-associated mortality and morbidity due to drug use, self-harm, and violence: changes during the COVID-19 pandemicR01HD102319 · NICHD · MICHIGAN STATE UNIVERSITY · PI Sidra Goldman-Mellor, Claire E Margerison · 2021 to 2026
$4.4M
NICHD NIH HHS R01 HD102319
6 · The paper itself

Abstract

introductionOpioid-related deaths among perinatal populations have increased sharply in the U.S. Whether the recent ascendance of illicit fentanyl and other synthetic opioids in the drug supply translates to an increase in prenatal opioid use disorder remains unknown. This study investigated whether California's comparatively late fentanyl influx, in 2019, was associated with a subsequent increase in opioid use disorder among pregnant people.

methodsThis ecologic, repeated retrospective cohort study examined annual cohorts of individuals with an index live-birth delivery in California from 2010 to 2022. Analyses used statewide, all-payer linked hospitalization and emergency department records. Overall and subgroup-specific trends in the prevalence of prenatal opioid use disorder, assessed using International Classification of Diseases, Ninth Revision, Clinical Modification/ICD-10-CM diagnoses recorded at delivery hospitalization and during prenatal emergency department visits, were examined using joinpoint and logistic regression analyses. Data analysis was conducted in 2025.

resultsThe study included 4,381,064 index deliveries. Between 2010 and 2022, the prevalence of prenatal opioid use disorder doubled (as assessed at delivery: 0.15%-0.30%; as assessed via prenatal opioid use disorder emergency department visits: 0.04%-0.08%). Joinpoint analysis indicated that most of this increase occurred before 2018, with annual percentage changes after 2018 being largely flat (annual percentage change in at-delivery prevalence, 2.4% [95% CI= -2.2%, 7.3%]; annual percentage change in emergency department visit prevalence, 1.4% [95% CI= -7.0%, 3.8%]). Differences in the 2019-2022 versus 2010-2018 prevalence of prenatal opioid use disorder were larger among non-Hispanic White and other/multiple race individuals, as well as those covered by Medicaid.

conclusionsThe recent introduction of fentanyl to California was associated with only incremental increases in the prevalence of prenatal opioid use disorder. Continued tracking of these trends is important for perinatal health.

Indexed as

Opioid-Related DisordersPregnancy ComplicationsAdultAnalgesics, OpioidCaliforniaEmergency Service, HospitalFemaleFentanylHospitalizationHumansPregnancyPrevalenceRetrospective StudiesYoung AdultAnalgesics, OpioidFentanyl

Identifiers

PMID40921307
PMCPMC12642814

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.